MX2010004315A - Compuestos para inhibir la actividad de quinesina ksp. - Google Patents

Compuestos para inhibir la actividad de quinesina ksp.

Info

Publication number
MX2010004315A
MX2010004315A MX2010004315A MX2010004315A MX2010004315A MX 2010004315 A MX2010004315 A MX 2010004315A MX 2010004315 A MX2010004315 A MX 2010004315A MX 2010004315 A MX2010004315 A MX 2010004315A MX 2010004315 A MX2010004315 A MX 2010004315A
Authority
MX
Mexico
Prior art keywords
compounds
ksp kinesin
kinesin activity
formula
inhibiting ksp
Prior art date
Application number
MX2010004315A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Dilrukshi Vitharana
Angie R Angeles
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010004315A publication Critical patent/MX2010004315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de fórmula (I), a continuación (ver fórmula (I)) (en donde Rl R2, R3, R27, R28, R29, p, E, anillo A y el anillo B son como se definen aquí); la presente invención también se relaciona con composiciones (incluyendo composiciones farmacéuticamente aceptables) que comprenden estos compuestos, solos y en combinación con uno o más agentes terapéuticos adicionales y con métodos para su uso en la inhibición de la actividad de quinesina KSP, y para tratar enfermedades proliferativas celulares o trastornos asociados con la actividad de quinesina KSP.
MX2010004315A 2007-11-09 2008-10-16 Compuestos para inhibir la actividad de quinesina ksp. MX2010004315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688007P 2007-11-09 2007-11-09
PCT/US2008/080179 WO2009061597A1 (en) 2007-11-09 2008-10-16 Compounds for inhibiting ksp kinesin activity

Publications (1)

Publication Number Publication Date
MX2010004315A true MX2010004315A (es) 2010-07-06

Family

ID=40210690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004315A MX2010004315A (es) 2007-11-09 2008-10-16 Compuestos para inhibir la actividad de quinesina ksp.

Country Status (7)

Country Link
US (1) US20110150757A1 (es)
EP (1) EP2217568A1 (es)
JP (1) JP2011503077A (es)
CN (1) CN101903343A (es)
CA (1) CA2702995A1 (es)
MX (1) MX2010004315A (es)
WO (1) WO2009061597A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200934785A (en) 2007-10-19 2009-08-16 Schering Corp Compounds for inhibiting KSP kinesin activity
US20100224248A1 (en) * 2009-02-20 2010-09-09 John Kenney Solar Modules Including Spectral Concentrators and Related Manufacturing Methods
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500848A1 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
US20110150757A1 (en) 2011-06-23
CA2702995A1 (en) 2009-05-14
EP2217568A1 (en) 2010-08-18
CN101903343A (zh) 2010-12-01
WO2009061597A1 (en) 2009-05-14
JP2011503077A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2013005543A (es) Metodo para el tratamiento de nefropatia inducida por contraste.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MX2013013692A (es) Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2).
TW200716628A (en) Novel compounds
IN2012DN00766A (es)
TW200800975A (en) New compounds 2
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MY153921A (en) Aminopyrazole derivatives
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal